
The 28th Annual Washington Clinical Laboratory Conference

“Trends & Strategies for 2022”

REGISTRATION FLYER



November 8, 2021

VIRTUAL EDITION

ONLINE REGISTRATION

Thank you for your interest in the laboratory conference. Our conference will again be in a virtual format and we are using MS Teams as the platform. In order to register for this conference, you will need to register online. Please use this [link](#) to register.

Three (3.0) P.A.C.E. credits are available for this program.

ASCLS-WA is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E.® Program.

CONFERENCE FEE: \$25.00.
PLEASE MAKE CHECKS PAYABLE TO: ASCLS-WA.
Send Checks to: Leonard Kargacin
PO Box 117
Mount Vernon, WA 98273

Agenda

- 9:00** **Welcome**
- 9:15 – 9:30** **Opening Remarks**
Romesh Gautam, PhD
Director, Washington State
Public Health Laboratories
- 9:30 – 10:30** **Keynote Address:**
“Lab Reimbursement & Policy Briefing: Irony of the New Normal”
Dennis Weissman
- 10:00 – 10:15** **Break**
- 10:45 – 11:45** ***“Emerging Infectious Diseases”***
Gregory Armstrong, MD
- 12:00 – 1:00** ***“COVID-19 in Washington State”***
Scott Lindquist, MD, MPH
- 1:00** **Wrap-up**

ASCLS-WA is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E.® Program.

SPEAKERS

Dennis Weissman

Dennis Weissman is a nationally known consultant and thought leader for the clinical laboratory and anatomic pathology sectors. Dennis is President of Dennis Weissman & Associates, LLC, a consultancy which provides market intelligence on Medicare and health care reform policies and strategies as well as business and financial trends affecting the health care industry. Dennis previously founded and served as publisher of Washington G-2 Reports (now G2 Intelligence), an information company that reports on the U.S. clinical laboratory industry via newsletters, research reports & conferences.

“Lab Reimbursement & Policy Briefing: Irony of the New Normal ”

The unprecedented public health crisis in the COVID era and the roller coaster effect it has had on the U.S. health care system has resulted in a turbulent ride which has been even more volatile for the nation’s clinical laboratories. Though labs have seen some key business and policy adjustments during the pandemic, this new normal has done little to alter industry pressure points relating to payment levels. Regulatory controls and consolidation trends and in the longer term, will likely accelerate them.



Gregory Armstrong, MD

Dr. Gregory Armstrong, MD Gregory Armstrong, MD, leads CDC’s Advanced Molecular Detection (AMD) initiative, a \$30m-per-year innovation and modernization program established in 2014 to bring next-generation genomic sequencing, bioinformatics, and related technology into public health in the United States. The program has touched almost every area of infectious-disease public health at CDC, transforming, for example, how outbreaks are detected and investigated, and how pathogens of all types are characterized. In addition to adapting AMD technologies for public health use, the program also manages CDC’s scientific high-performance computing infrastructure, develops and oversees training of microbiologists and epidemiologists in this emerging field, and supports public-health departments across the United States to bring the technology on board.

“Emerging Infectious Diseases”

An infectious diseases physician by background, Dr. Armstrong has particular expertise in the epidemiology of viral infectious diseases and in mathematical modeling of disease incidence and burden. Since joining CDC in 1997, he has worked in the fields of viral hepatitis and refugee health, served as chief of CDC’s viral vaccine-preventable diseases epidemiology branch, and led CDC’s component of the Global Polio Eradication Initiative during a critical intensification of the program from 2012 through 2015. Dr. Armstrong will discuss the role of the CDC in identifying and monitoring emerging infectious diseases facing the United States.



Scott Lindquist, MD, MPH

Scott Lindquist, MD, MPH, completed his medical training at the University of Washington School of Medicine as a student of the WAMI (Washington, Alaska, Montana, and Idaho) program. He completed a residency in pediatrics at the University of North Carolina at Chapel Hill and an Infectious Disease Fellowship at Baylor College of Medicine in Houston, Texas. He completed his Masters in Public Health at the Harvard School of Public Health. Dr. Lindquist has drawn upon this broad background to focus upon underserved populations and infectious diseases. He has combined all the aspects of his training as a Health Officer/Director of Health for the Kitsap County Health District from 2001–2014. In addition, he serves as a pediatrician and public health officer at the Port Gamble S’Klallam Tribal Medical Clinic where he has worked one day a week since 2001. Dr. Lindquist has been the Washington State Tuberculosis medical consultant since 2002 and currently serves as the State Epidemiologist for Communicable Diseases and Deputy Health Officer for Washington State.

“COVID-19 in Washington State”

This presentation will cover the epidemiology of COVID-19 in the world, U.S. and Washington State. This will include detailed molecular genotyping results from our local cases.